Mark Kirschbaum
Mark Kirschbaum
Professor of Medicine, Penn State Hershey Medical Center
Verified email at
Cited by
Cited by
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of …
S Slavin, A Nagler, E Naparstek, Y Kapelushnik, M Aker, G Cividalli, ...
Blood, The Journal of the American Society of Hematology 91 (3), 756-763, 1998
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ...
Journal of clinical oncology 27 (32), 5410, 2009
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ...
Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011
Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ...
Clinical Cancer Research 22 (4), 868-876, 2016
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, ...
Journal of Clinical Oncology 30 (18), 2197-2203, 2012
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in …
A Nademanee, S Forman, A Molina, H Fung, D Smith, A Dagis, C Kwok, ...
Blood 106 (8), 2896-2902, 2005
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
M Kirschbaum, P Frankel, L Popplewell, J Zain, M Delioukina, V Pullarkat, ...
Journal of clinical oncology 29 (9), 1198, 2011
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph acute lymphoblastic leukemia cells
A Scuto, M Kirschbaum, C Kowolik, L Kretzner, A Juhasz, P Atadja, ...
Blood, The Journal of the American Society of Hematology 111 (10), 5093-5100, 2008
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
EJ Dann, R Bar-Shalom, A Tamir, N Haim, M Ben-Shachar, I Avivi, ...
Blood 109 (3), 905-909, 2007
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
M Kirschbaum, I Gojo, SL Goldberg, C Bredeson, LA Kujawski, A Yang, ...
British journal of haematology 167 (2), 185-193, 2014
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
N Jain, E Curran, NM Iyengar, E Diaz-Flores, R Kunnavakkam, ...
Clinical cancer research 20 (2), 490-498, 2014
HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen
N Li, D Zhao, M Kirschbaum, C Zhang, CL Lin, I Todorov, F Kandeel, ...
Proceedings of the National Academy of Sciences 105 (12), 4796-4801, 2008
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels
L Kretzner, A Scuto, PM Dino, CM Kowolik, J Wu, P Ventura, R Jove, ...
Cancer research 71 (11), 3912-3920, 2011
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas
F Yang, TE Van Meter, R Buettner, M Hedvat, W Liang, CM Kowolik, ...
Molecular cancer therapeutics 7 (11), 3519-3526, 2008
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
F Lopez, P Parker, A Nademanee, R Rodriguez, Z Al-Kadhimi, R Bhatia, ...
Biology of Blood and Marrow Transplantation 11 (4), 307-313, 2005
Chronic graft-versus-host disease treated with UVB phototherapy
CD Enk, S Elad, A Vexler, J Kapelushnik, R Gorodetsky, M Kirschbaum
Bone marrow transplantation 22 (12), 1179-1183, 1998
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
MH Kirschbaum, BH Goldman, JM Zain, JR Cook, LM Rimsza, SJ Forman, ...
Leukemia & lymphoma 53 (2), 259-262, 2012
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
R Chen, P Frankel, L Popplewell, T Siddiqi, N Ruel, A Rotter, SH Thomas, ...
Haematologica 100 (3), 357, 2015
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia …
MH Kirschbaum, KA Foon, P Frankel, C Ruel, B Pulone, JM Tuscano, ...
Leukemia & lymphoma 55 (10), 2301-2304, 2014
Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
Y Oki, D Buglio, J Zhang, Y Ying, S Zhou, A Sureda, D Ben-Yehuda, ...
Blood cancer journal 4 (8), e236-e236, 2014
The system can't perform the operation now. Try again later.
Articles 1–20